Objectives: To obtain reliable data on quality of care of rosacea and to compare care indicators with those found in atopic dermatitis and psoriasis. Patients and Methods: In this cross-sectional study, clinical history, health-related quality of life (HrQoL), medication and treatment benefit of patients with rosacea were assessed by standardized questionnaires. Data were compared to patients with atopic dermatitis and psoriasis. Results: Almost all 475 participants (96.4%) had received topical therapy. 24% had used cortisone ointments. The mean Dermatology Life Quality Index (DLQI) was 4.3 ± 4.6 (atopic dermatitis: 8.5 ± 6.0, psoriasis: 6.7 ± 6.2). The Patient Benefit Index (patient-defined therapeutic benefit) was 1.9 ± 1.2 (psoriasis: 2.3 ± 1.1, atopic dermatitis: 2.1 ± 1.1). Conclusions: Only a small proportion of the rosacea patients had substantial impairments in HrQoL. Overall, their burden appears to be lower than in patients with atopic dermatitis or psoriasis. However, the lower therapeutic benefit and the high proportion of topical steroid use indicate a need for optimized therapy.

Keywords:
Quality of life, Rosacea, Health services research, Patient advocacy groups
1.
Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I: Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers. Br J Dermatol 2011 DOI: 10.1111/j.1365-2133.2011.10436.x.
2.
Shuster S, Fisher GH, Harris E, Binnell D: The effect of skin disease on self image. Br J Dermatol 1978;99:18–19.
3.
Roosta N, Black DS, Peng D, Riley LW: Skin disease and stigma in emerging adulthood: impact on healthy development. J Cutan Med Surg 2010;14:285–290.
4.
Salamon M, Chodkiewicz J, Sysa-Jedrzejowska A, Wozniacka A: Quality of life in patients with rosacea. Przegl Lek 2008;65:385–389.
5.
Chodkiewicz J, Salamon M, Miniszewska J, Woźniacka A: Psychosocial impact of rosacea. Przegl Lek 2007;64:997–1001.
6.
Gupta MA, Gupta AK, Chen SJ, Johnson AM: Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey – Outpatient Department Data collected by the U.S. National Center for Health Statistics from 1995 to 2002. Br J Dermatol 2005;153:1176–1181.
7.
Gieler U, Niemeier V, Kupfer J, Brosig B, Schill, WB: Psychosomatische Dermatologie in Deutschland: eine Umfrage an 69 Hautkliniken. Hautarzt 2001;52:104–110.
8.
Kerscher M, Reuther T: Der Fluch der Kelten – kosmetische Aspekte bei der Rosazea; in Schöfer H (ed): Rosazea: Klinik und aktuelle Therapie. Stuttgart, Georg Thieme, 2003, pp 67–72.
9.
Gauwerky K, Klövekorn W, Korting HC, Lehmann P, Meigel EM, Reinel D, Ruzicka T, Schaller M, Schöfer H, Tietze J: Rosazea: Leitlinien der Deutschen Dermatologischen Gesellschaft (DDG) [Treatment of rosacea. German National Guideline] [Internet]. University of Düsseldorf: AWMF online; 2008 Dec [cited 15.09.2010]. Available from: http://www.uni-duesseldorf.de/AWMF/ll/013-065.htm#60.
10.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–216.
11.
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY: The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008;159:997–1035.
12.
Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ: Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002;47:512–518.
13.
Augustin M, Reich C, Schaefer I, Zschocke I, Rustenbach SJ: Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne. J Dtsch Dermatol Ges 2008;6:113–120.
14.
Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schäfer I, Reusche M, Mielke V, Rustenbach SJ: The patient benefit index: a novel approach in patient-defined outcome measurement for skin diseases. Arch Dermatol Res 2009;301:561–571.
15.
Augustin M, Kruger K, Radtke MA, Schwippl I, Reich K: Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008;216:366–372.
16.
Augustin M, Reich K, Reich C, Purwins S, Rustenbach SJ, Schäfer I, Radtke M: Quality of psoriasis care in Germany-results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 2008;6:640–645.
17.
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY: Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 2005;125:659–664.
18.
Coughlin SS: Recall bias in epidemiologic studies. J Clin Epidemiol 1990;43:87–91.
19.
Leyden JJ, Thew M, Kligman AM: Steroid rosacea. Arch Dermatol 1974;111:619–622.
20.
Nicholson K, Abramova L, Chren M, Yeung J, Chon SY, Chen SC: A pilot quality-of-life instrument for acne rosacea. J Am Acad Dermatol 2007;57:213–221.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.